Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 18, 2008

Beckman Coulter Obtains Full Rights to Nephromics’ Preeclampsia Test

  • Beckman Coulter has bought its royalty obligations to Nephromics, which covers a preeclampsia test in development. In addition, Beckman Coulter obtained rights to acquire the worldwide diagnostics assets of Nephromics.

    Beckman Coulter has began evaluating the preeclampsia product in a clinical trial. The new tests are being designed for detection, monitoring, and risk assessment. The company plans to begin offering the tests by the end of 2009.

    The device is undergoing development on the company's family of UniCel® DxI and Access® immunoassay systems as well as UniCel DxCi chemistry-immunoassay work cells.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »